Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Selected Balance Sheet Data (Details Textual)

v3.7.0.1
Note 2 - Selected Balance Sheet Data (Details Textual)
3 Months Ended 9 Months Ended
Dec. 31, 2016
USD ($)
Mar. 31, 2017
USD ($)
Mar. 31, 2016
USD ($)
Aug. 01, 2016
USD ($)
Jun. 30, 2016
USD ($)
Available-for-sale Securities   $ 53,800,000     $ 31,600,000
Payments to Acquire Available-for-sale Securities   1,625,000    
Inventory, Net   63,767,000     57,102,000
Inventory Valuation Reserves   $ 24,000,000     24,000,000
Number of Reporting Units   3      
Other Assets, Noncurrent   $ 42,812,000     1,922,000
Payments to Acquire Investments   40,000,000    
Goodwill, Impairment Loss   0      
Astute Medical, Inc. [Member]          
Payments to Acquire Investments $ 40,000,000        
ChemoCentryx, Inc (CCXI) [Member]          
Available-for-sale Equity Securities, Gross Unrealized Gain   16,900,000      
Available-for-sale Equity Securities, Amortized Cost Basis   29,500,000     $ 29,500,000
Certificates Of Deposit [Member] | CHINA          
Payments to Acquire Available-for-sale Securities   1,300,000      
Advanced Cell Diagnostics (ACD) [Member]          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory       $ 7,000,000  
Advanced Cell Diagnostics (ACD) [Member] | Available-for-sale Securities [Member]          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities   $ 3,100,000